Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

  • Partnership between Cantourage, Cannabis House and Together Pharma brings Ugandan medical cannabis to Poland for the first time.
  • Poland marks the third European market, following the UK and Germany, in which the product is now available to patients.
  • Glueberry OG ® cultivar will further increase therapy options for medical cannabis patients in Poland.

Berlin, 1 December 2022 – Cantourage Group SE (FRA: HIGH), a European medical cannabis leader, Cannabis House, an initiative enabling the distribution of medical cannabis in Poland, and Together Pharma (TASE: TGTR), an Israeli producer of medical cannabis, today announced a partnership that makes Ugandan medical cannabis available in Poland for the first time. From the first week of December, Polish patients enrolled in the Cannabis House initiative will have access to Together Pharma’s Glueberry OG® cultivar, which will be distributed via selected pharmacies across the country. After Germany and the UK, Poland marks the third European market in which the product will now be available.

The supply agreement includes the importation of more than 500 kg of finished dried cannabis flowers over the upcoming three years. More products, already offered by Cantourage in the UK and Germany, will be introduced to the initiative in Poland in the coming months.

Philip Schetter, CEO of Cantourage, says: “We are excited to join forces with Cannabis House and Together Pharma to expand access to medical cannabis products for patients in Poland. We feel privileged to play a part in supplying Polish patients with high quality cannabis from Uganda and in time, broadening the portfolio of products available.”

Dr. Grzegorz Kobyłecki, CEO of Cannabis House, adds: “Today, demand for medical cannabis in Poland is at an all-time high. The cannabis market in Poland has quadrupled over the last three years. Therefore, our partnership is an important step in ensuring that enough quality products will be available to patients. It should be emphasized that the experiment is not a clinical trial, but an initiative which holds bio-ethics approval. Given that cannabis from an unknown source could potentially contain mixtures of dangerous and addictive substances, we are proud to partner with companies such as Cantourage, who support us with high quality research material. Furthermore, given that the experiment has a three-year duration, we have worked hard to partner with groups with a stable market position.”

Nir Sosinsky, Managing Director of Together Pharma, states: “Our partnership with Cantourage continues to flourish and this latest development is extremely exciting for Together Pharma. The export of our products to Poland represents a new stage in the expansion of our global reach and strengthens our position in Europe, which is an important market for us. We are glad that our medical-grade cannabis flowers are being made available through Cantourage and Cannabis House in Poland, allowing for a sustainable supply to the benefit of patients across the country.”


About Cantourage

Cantourage is a publicly listed, leading European medical cannabis company. The Berlin-based company with subsidiaries in the United Kingdom and Poland, was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. Cantourage enables producers from all over the world to become part of the rapidly growing European medical cannabis market in a faster and more cost-effective way, while guaranteeing and developing the highest European quality standards. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol. The company was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under the stock ticker “HIGH”. For more information visit:


About Together Pharma Holdings Inc.

Together Pharma is a public company traded on the Tel Aviv Stock Exchange (TASE). The company has a subsidiary Globus Pharma Ltd., which holds the franchise, (both directly and through subsidiaries), to grow, produce, and distribute medical cannabis products.

The company operates two farms of the world’s most advanced agricultural cultivation systems, one in Israel and the second in Uganda, which allow the control and supervision of cannabis plants using the latest technologies, developing them into quality plants suitable for supervised medical use according to the strict IMC-GAP and GACP standards. The company has also a pharmaceutical factory, which meet all the required strict conditions for manufacturing medical products according to the IMC-GMP standard.


About Cannabis House

The Cannabis House initiative brings together a team of specialists in the field of medical cannabis. Their main goal is to gather patients, institutions, and companies in order to create dedicated cannabis research clusters. As the leader of the first social experiment in Poland, the study – comprising an initial group of 4,000 patients - aims to demonstrate the efficacy of reducing the use of synthetic psychoactive substance with high quality cannabis material. Our main thesis is that cannabis is an "exit drug not an entry drug".


This announcement does not constitute a public offer or an advertisement for a public offer within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company's financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.

In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as "Relevant Persons"). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.

Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.